{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:10:10Z","timestamp":1758971410442,"version":"3.44.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.annder.2011.09.013","type":"journal-article","created":{"date-parts":[[2011,11,7]],"date-time":"2011-11-07T23:34:47Z","timestamp":1320708887000},"page":"821-825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Choix th\u00e9rapeutique en fonction du contexte clinique"],"prefix":"10.1016","volume":"138","author":[{"given":"C.","family":"Paul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Bachelez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2011.09.013_bib0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1468-3083.2009.03563.x","article-title":"What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature","volume":"24","author":"Bronsard","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2011.09.013_bib0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1468-3083.2009.03562.x","article-title":"What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature","volume":"24","author":"Puzenat","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2011.09.013_bib0015","doi-asserted-by":"crossref","unstructured":"Paul C, Bachelez H. Traitement du psoriasis en pratique pour le rhumatologue. Revue du rhumatisme monographies 2011;78:145\u201351.","DOI":"10.1016\/j.monrhu.2011.03.002"},{"key":"10.1016\/j.annder.2011.09.013_bib0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1468-3083.2011.03991.x","article-title":"Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity","volume":"25","author":"Montaudi\u00e9","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2011.09.013_bib0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1468-3083.2007.02429.x","article-title":"Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study","volume":"22","author":"Gisondi","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2011.09.013_bib0030","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.annder.2011.09.013_bib0035","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jaad.2009.03.047","article-title":"Psoriasis in patients with HIV infection: from the medical board of the national psoriasis foundation","volume":"62","author":"Menon","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2011.09.013_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2011.09.013_bib0045","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.jaad.2009.03.044","article-title":"Treatment of psoriasis in patients with hepatitis C: from the medical board of the national psoriasis foundation","volume":"61","author":"Frankel","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2011.09.013_bib0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-3083.2011.03992.x","article-title":"Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis","volume":"25","author":"Maza","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2011.09.013_bib0055","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1468-3083.2011.03993.x","article-title":"Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review","volume":"25","author":"Sbidian","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963811004078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963811004078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:57:55Z","timestamp":1758970675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963811004078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0151963811004078"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2011.09.013","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Choix th\u00e9rapeutique en fonction du contexte clinique","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2011.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}